Catalyst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPRX)

$3.43 -0.10 (-2.83 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$3.43
Today's Range$3.42 - $3.59
52-Week Range$1.08 - $4.51
Volume315,835 shs
Average Volume505,717 shs
Market Capitalization$286.78 million
P/E Ratio-16.33
Dividend YieldN/A
Beta1.35

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CPRX
CUSIPN/A
Phone+1-305-5292522

Debt

Debt-to-Equity RatioN/A
Current Ratio12.60%
Quick Ratio12.60%

Price-To-Earnings

Trailing P/E Ratio-16.3333333333333
Forward P/E Ratio-15.59
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book7.30

Profitability

Trailing EPS($0.21)
Net Income$-18,070,000.00
Net MarginsN/A
Return on Equity-48.86%
Return on Assets-45.62%

Miscellaneous

Employees18
Outstanding Shares102,470,000

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) released its earnings results on Wednesday, May, 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). View Catalyst Pharmaceuticals' Earnings History.

When will Catalyst Pharmaceuticals make its next earnings announcement?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Catalyst Pharmaceuticals.

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2018?

4 brokers have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $5.00 to $8.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $6.25 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.

What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:

  • 1. HC Wainwright analysts commented, "AT-014 Conditional Approval: Further Attestation to Strategy AT-014 receives a conditional licensure from the USDA. On December 20, Aratana announced that the USDA Center for Veterinary Biologics has granted AT-014 conditional marketing approval for the treatment of canine osteosarcoma. AT-014 is a canine cancer vaccine derived from listeria that targets HER2/neu, a causative mutation of canine osteosarcoma. In pilot studies, AT-014 treatment of dogs with osteosarcoma (n=18) increased their median overall survival (mOS) to 956 days compared to 423 days for historical controls (p<0.05). Therefore, following the USDA approval we believe that AT-014 can quickly become a preferred therapeutic option for this difficult-to-treat indication. With four product approvals in two years, we believe the success of AT-014 is a further attestation of management's strategy of bringing advanced human therapies to the veterinarian market."" (12/21/2017)
  • 2. According to Zacks Investment Research, "Catalyst Pharma posted narrower than expected loss in the third quarter of 2017. Earlier in 2016, the company received a refusal to file letter from the FDA in connection with the NDA for Firdapse. The company suffered a setback when it received a refusal to file letter for Firdapse from the FDA.  Nevertheless, the company expects to report top-line results from its second phase III study of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in early December 2017 and resubmit a new drug application (NDA) before the end of 2017. Catalyst has a limited number of candidates in its pipeline and is highly dependent on Firdapse’s approval for growth.  Meanwhile, the company is also developing Firdapse for additional indications. The company’s share price movement shows that the stock has outperformed the industry year to date. " (11/14/2017)

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:

  • Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer (Age 68)
  • Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer (Age 44)
  • Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer (Age 53)
  • David D. Muth, Executive Vice President, Chief Commercial Officer (Age 60)
  • M. Douglas Winship, Vice President - Regulatory Operations (Age 66)
  • David J. Caponera, Vice President - Patient Advocacy & Reimbursement (Age 58)
  • Bernardino Mosquera M.D., Vice President - Clinical Operations (Age 47)
  • Charles B. O'Keeffe, Lead Independent Director (Age 75)
  • Gary Ingenito M.D., Chief Medical Officer (Age 52)
  • Richard J. Daly, Director (Age 64)

Who owns Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (6.93%), Consonance Capital Management LP (4.37%), BlackRock Inc. (3.92%), Millennium Management LLC (2.02%), Emerald Advisers Inc. PA (1.34%) and Driehaus Capital Management LLC (1.20%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany and Philip H Coelho. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Who sold Catalyst Pharmaceuticals stock? Who is selling Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Berson & Corrado Investment Advisors LLC. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Millennium Management LLC, Emerald Advisers Inc. PA, Driehaus Capital Management LLC, EAM Investors LLC, Mangrove Partners, Sphera Funds Management LTD. and Renaissance Technologies LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany and Philip H Coelho. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $3.43.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $286.78 million. The biopharmaceutical company earns $-18,070,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 18 workers across the globe.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 Alhambra Cir Ste 1250, CORAL GABLES, FL 33134-5038, United States. The biopharmaceutical company can be reached via phone at +1-305-5292522 or via email at [email protected]


MarketBeat Community Rating for Catalyst Pharmaceuticals (CPRX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catalyst Pharmaceuticals (NASDAQ:CPRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.25$6.25$5.50$5.67
Price Target Upside: 60.67% upside60.67% upside83.95% upside96.76% upside

Catalyst Pharmaceuticals (NASDAQ:CPRX) Consensus Price Target History

Price Target History for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2017HC WainwrightReiterated RatingBuy$6.00HighView Rating Details
12/1/2017Piper Jaffray CompaniesSet Price TargetPositive -> Buy$8.00LowView Rating Details
11/29/2017SunTrust BanksReiterated RatingBuy$6.00HighView Rating Details
11/1/2017Roth CapitalSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earnings History and Estimates Chart

Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ CPRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.06)N/AView Earnings Details
11/8/2017Q3 2017($0.06)($0.05)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.05)ViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
5/16/2014Q1 2014($0.08)($0.06)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
5/16/2013Q1 2013($0.07)($0.04)ViewN/AView Earnings Details
4/2/2013Q4 2012($0.05)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.04)($0.01)ViewN/AView Earnings Details
5/16/2012Q1 2012($0.08)($0.04)ViewN/AView Earnings Details
4/2/2012Q4 2011($0.06)($0.09)ViewN/AView Earnings Details
11/15/2011Q3 2011($0.07)($0.05)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.08)($0.06)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.08)ViewN/AView Earnings Details
4/1/2011Q4 2010($0.07)($0.04)ViewN/AView Earnings Details
11/16/2010Q3 2010($0.09)($0.05)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.07)($0.07)ViewN/AView Earnings Details
5/18/2010Q1 2010($0.06)ViewN/AView Earnings Details
4/1/2010Q4 2009($0.06)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.11)($0.09)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.20)($0.13)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.29)($0.22)ViewN/AView Earnings Details
3/27/2009Q4 2008($0.27)($0.27)ViewN/AView Earnings Details
11/14/2008Q3 2008($0.22)ViewN/AView Earnings Details
8/15/2008Q2 2008($0.14)($0.19)ViewN/AView Earnings Details
5/16/2008Q1 2008($0.12)($0.13)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.07)($0.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Catalyst Pharmaceuticals (NASDAQ:CPRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.22 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 36.92%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ CPRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/5/2017Patrick J McenanyInsiderBuy20,000$2.58$51,600.004,471,026View SEC Filing  
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00432,126View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00159,987View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00100,000View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.004,393,109View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00412,126View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.004,287,809View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00158,287View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00392,126View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40457,687View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00377,126View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.0050,000View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.004,237,809View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00372,126View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00367,126View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.0074,131View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.004,137,262View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.003,656,247View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00192,126View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00182,126View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.003,631,247View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00177,126View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catalyst Pharmaceuticals (NASDAQ CPRX) News Headlines

Source:
DateHeadline
Catalyst Pharmaceutical (CPRX) Presents At BIO CEO & Investor Conference - SlideshowCatalyst Pharmaceutical (CPRX) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:43 PM
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
finance.yahoo.com - February 12 at 9:44 AM
Catalyst Pharmaceuticals to Present at Two Upcoming Investor ConferencesCatalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:34 AM
Catalyst Pharmaceuticals Inc (CPRX) Expected to Announce Earnings of -$0.06 Per ShareCatalyst Pharmaceuticals Inc (CPRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - January 27 at 9:14 PM
Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from BrokeragesCatalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 3:24 AM
Contrasting TESARO (TSRO) & Catalyst Pharmaceuticals (CPRX)Contrasting TESARO (TSRO) & Catalyst Pharmaceuticals (CPRX)
www.americanbankingnews.com - January 25 at 10:34 AM
Catalyst Pharmaceuticals Inc (CPRX) Sees Significant Decline in Short InterestCatalyst Pharmaceuticals Inc (CPRX) Sees Significant Decline in Short Interest
www.americanbankingnews.com - January 15 at 4:40 AM
-$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter-$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter
www.americanbankingnews.com - January 10 at 9:16 PM
Catalyst Pharmaceuticals (CPRX) Rating Lowered to Hold at BidaskClubCatalyst Pharmaceuticals (CPRX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - January 6 at 7:28 PM
Catalyst Pharmaceuticals Inc (CPRX) Given Average Rating of "Buy" by BrokeragesCatalyst Pharmaceuticals Inc (CPRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 1 at 6:22 AM
Catalyst Pharmaceuticals (CPRX) Given a $8.00 Price Target at Piper Jaffray CompaniesCatalyst Pharmaceuticals (CPRX) Given a $8.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - December 30 at 5:52 PM
What Drives Catalyst Pharmaceuticals Above 250% This Year?What Drives Catalyst Pharmaceuticals Above 250% This Year?
www.nasdaq.com - December 28 at 12:17 PM
Catalyst Pharmaceuticals (CPRX) "Buy" Rating Reiterated at HC WainwrightCatalyst Pharmaceuticals' (CPRX) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - December 21 at 3:50 PM
Catalyst Pharmaceuticals (CPRX) Rating Lowered to Buy at BidaskClubCatalyst Pharmaceuticals (CPRX) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - December 9 at 7:16 PM
Reviewing Vertex Pharmaceuticals (VRTX) & Catalyst Pharmaceuticals (CPRX)Reviewing Vertex Pharmaceuticals (VRTX) & Catalyst Pharmaceuticals (CPRX)
www.americanbankingnews.com - December 9 at 1:48 AM
 Analysts Expect Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 EPS Analysts Expect Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 EPS
www.americanbankingnews.com - December 7 at 5:28 PM
Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Buy" from AnalystsCatalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 6:26 AM
Catalyst Pharmaceuticals (CPRX) "Buy" Rating Reaffirmed at SunTrust BanksCatalyst Pharmaceuticals' (CPRX) "Buy" Rating Reaffirmed at SunTrust Banks
www.americanbankingnews.com - November 29 at 4:44 PM
Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common StockCatalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock
finance.yahoo.com - November 28 at 5:16 PM
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in ... - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in ... - GlobeNewswire (press release)
globenewswire.com - November 28 at 8:34 AM
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 28 at 8:34 AM
Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial ofCatalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of
www.nasdaq.com - November 27 at 6:11 PM
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockCatalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - November 27 at 6:11 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research to "Sell"Catalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 25 at 12:14 PM
Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy ... - GlobeNewswire (press release)Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy ... - GlobeNewswire (press release)
globenewswire.com - November 23 at 4:15 AM
In The Spotlight: Catalyst Pharmaceuticals - Nasdaq.com - NasdaqIn The Spotlight: Catalyst Pharmaceuticals - Nasdaq.com - Nasdaq
www.nasdaq.com - November 20 at 3:04 AM
In The Spotlight: Catalyst PharmaceuticalsIn The Spotlight: Catalyst Pharmaceuticals
www.rttnews.com - November 19 at 5:00 PM
FY2020 EPS Estimates for Catalyst Pharmaceuticals, Inc. Lowered by Analyst (CPRX)FY2020 EPS Estimates for Catalyst Pharmaceuticals, Inc. Lowered by Analyst (CPRX)
www.americanbankingnews.com - November 13 at 10:30 AM
Catalyst Pharmaceuticals, Inc. (CPRX) Receives "Buy" Rating from HC WainwrightCatalyst Pharmaceuticals, Inc. (CPRX) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - November 10 at 10:24 AM
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 - NasdaqCatalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 - Nasdaq
www.nasdaq.com - November 10 at 5:56 AM
Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update - NasdaqCatalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update - Nasdaq
www.nasdaq.com - November 9 at 3:07 AM
Have Investors Already Priced In Catalyst Pharmaceuticals Inc’s (CPRX) Growth?Have Investors Already Priced In Catalyst Pharmaceuticals Inc’s (CPRX) Growth?
finance.yahoo.com - November 8 at 10:06 PM
Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateCatalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 10:06 PM
Catalyst reports 3Q lossCatalyst reports 3Q loss
finance.yahoo.com - November 8 at 10:06 PM
What's in Store for Catalyst (CPRX) This Earnings Season?What's in Store for Catalyst (CPRX) This Earnings Season?
finance.yahoo.com - November 6 at 6:46 PM
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017
finance.yahoo.com - November 1 at 6:22 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by SunTrust Banks, Inc. AnalystsCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by SunTrust Banks, Inc. Analysts
www.americanbankingnews.com - November 1 at 3:22 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by Roth Capital AnalystsCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - November 1 at 3:22 PM
Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic SyndromeCatalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome
finance.yahoo.com - October 31 at 6:42 PM
Catalyst Pharmaceuticals, Inc. (CPRX) to Release Earnings on TuesdayCatalyst Pharmaceuticals, Inc. (CPRX) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:08 AM
Analyzing Catalyst Pharmaceuticals (CPRX) & Chimerix (CMRX)Analyzing Catalyst Pharmaceuticals (CPRX) & Chimerix (CMRX)
www.americanbankingnews.com - October 21 at 8:14 AM
Catalyst Pharmaceutical (CPRX) Presents At 2017 BIO Investor Forum - SlideshowCatalyst Pharmaceutical (CPRX) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 19 at 6:01 PM
Catalyst Pharmaceuticals (CPRX) & Its Peers Critical AnalysisCatalyst Pharmaceuticals (CPRX) & Its Peers Critical Analysis
www.americanbankingnews.com - October 19 at 6:26 AM
Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor ForumCatalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum
finance.yahoo.com - October 16 at 6:14 PM
Catalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment ResearchCatalyst Pharmaceuticals, Inc. (CPRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 12 at 12:20 AM
Catalyst Pharmaceuticals (CPRX) versus Endocyte (ECYT) Head to Head ReviewCatalyst Pharmaceuticals (CPRX) versus Endocyte (ECYT) Head to Head Review
www.americanbankingnews.com - September 30 at 2:24 PM
Short Interest in Catalyst Pharmaceuticals, Inc. (CPRX) Declines By 35.4%Short Interest in Catalyst Pharmaceuticals, Inc. (CPRX) Declines By 35.4%
www.americanbankingnews.com - September 29 at 1:28 AM
-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter
www.americanbankingnews.com - September 22 at 4:28 PM
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates - NasdaqCatalyst (CPRX) Focused on Two Lead Pipeline Candidates - Nasdaq
www.nasdaq.com - September 19 at 10:31 PM
Catalyst (CPRX) Focused on Two Lead Pipeline CandidatesCatalyst (CPRX) Focused on Two Lead Pipeline Candidates
finance.yahoo.com - September 18 at 5:28 PM

SEC Filings

Catalyst Pharmaceuticals (NASDAQ:CPRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catalyst Pharmaceuticals (NASDAQ:CPRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catalyst Pharmaceuticals (NASDAQ CPRX) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.